問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Study Site

Study Site



Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 1,704

    Total Beds

  • 806

    Total Doctors

  • ctc@ms.kmuh.org.tw
  • Yu-Sam Lin
  • 886-7-3121101#6643
  • 807Kaohsiung CityKaohsiung SanminNo.100, Tzyou 1st Rd., Sanmin Dist.,Sanmin,Kaohsiung City 807

Recruiting Trial

537Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1238Cases

2014-12-01 - 2018-11-30

Phase III

A Phase 3, Double-Blind, Randomized, Parallel-Group, Active-Controlled Study to Compare the Efficacy and Safety of CT-P6 and Herceptin as Neoadjuvant and Adjuvant Treatment in Patients with HER2-Positive Early Breast Cancer

  • Condition/Disease

    HER2-Positive Early Breast Cancer

  • Test Drug

    CT-P6

Participate Sites
7Sites

Terminated7Sites

2015-07-01 - 2019-12-16

Phase III

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    Atezolizumab (MPDL3280A)

Participate Sites
12Sites

Terminated12Sites

2015-05-01 - 2023-04-24

Phase III

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

  • Condition/Disease

    Multiple Myeloma

  • Test Drug

    Ixazomib (MLN9708)

Participate Sites
4Sites

Terminated3Sites

蕭惠樺
Kaohsiung Municipal Gangshan Hospital

未分科

2015-07-01 - 2019-12-16

Phase III

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating The Efficacy And Safety Of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel Or MPDL3280A In Combination With Carboplatin + Nab-Paclitaxel Versus Carboplatin + Nab-Paclitaxel In Chemotherapy-Naïve Patients With Stage IV Squamous Non-Small Cell Lung Cancer

  • Condition/Disease

    Squamous Non-Small Cell Lung Cancer

  • Test Drug

    MPDL3280A

Participate Sites
13Sites

Terminated13Sites

2010-10-01 - 2016-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2011-11-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2012-06-01 - 2014-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Study ended6Sites

2010-04-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Study ended7Sites

2007-11-01 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2007-11-01 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

1 91 92 93 94 95 124
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB